Amitriptyline normalizes tetrabenazine-induced changes in cerebral microcirculation

https://doi.org/10.1016/0006-3223(86)90190-3Get rights and content

Abstract

The cerebromicrocirculation in the tetrabenzaine (TBZ) model of depression has been found to be abnormal with respect to (1) responsiveness of cerebral blood flow to increases in arterial CO2 content and (2) the effective permeability of the blood-brain barrier to water. Development of these abnormalities temporally paralleled the behavioral disturbances and catecholamine depletion induced by TBZ. These TBZ-induced changes occurred globally throughout the brain, being apparent in the forebrain, cerebellum, and medulla-pons. Pretreatment with the antidepressant amitriptyline prevented both behavioral and physiological effects of TBZ, whereas amitriptyline administered after TBZ was less effective. The results suggest that an important action of tricyclic antidepressants may be cerebromicrocirculatory effects.

References (23)

  • SI Harik et al.

    Cerebral norepinephrine: Influence on cortical oxidative metabolism in situ

    Science

    (1979)
  • Cited by (9)

    • Neurobiological basis of motivational deficits in psychopathology

      2015, European Neuropsychopharmacology
      Citation Excerpt :

      The effects of tetrabenazine on effort-related decision making were reversed by the adenosine A2A antagonist MSX-3 and the antidepressant bupropion, which blocks catecholamine uptake. These results demonstrate that tetrabenazine, which is used in animal models to produce depression-like effects (Preskorn et al., 1984; Kent et al., 1986; Wang et al.. 2010), can alter effort-related choice behavior. Taken together, these preclinical results are consistent with human studies of effort-related decision making showing that decreased selection of high effort/high reward options is seen in patients with major depression (Treadway et al., 2012b).

    • Mesolimbic dopamine and the regulation of motivated behavior

      2016, Current Topics in Behavioral Neurosciences
    View all citing articles on Scopus

    Supported in part by a Clinical Pharmacology Fellowship from the Pharmaceutical Manufacturers Association Foundation (T.A.K.) and by NINDCS Grant NS-17252 and NIMH Research Scientist Development Award MH-00272 (S.H.P.).

    View full text